Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Genes, chromosomes & cancer - 1 Jan 2015

Kim Myungshin, Lee Shin Hyo, Kim Jiyeon, Lee Sung-Eun, Kim Yoo-Jin, Min Chang-Ki

Abstract excerpt

We performed single nucleotide polymorphism (SNP) array analysis of 35 newly diagnosed symptomatic multiple myeloma (MM) patients who received bortezomib-melphalan-prednisone (VMP) to identify collaborating genetic events that could predict the outcome of treatment. A total of 340 copy number variations (CNVs) were identified, with the most frequently identified CNVs being gains on 1q, 19p, 9q, 3q, 9p, 15q, 19q,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Chromosomes, Human

Share to Melphalan

Share to Multiple Myeloma

Share to Prednisone

Share to Pyrazines

Source

Identifiers

PMID: 25145975
DOI: 10.1002/gcc.22213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.PMID 25145975Read ↗

Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma.Semantic proximity Read ↗

Prognostic significance of copy-number alterations in multiple myeloma.Semantic proximity Read ↗

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status.Semantic proximity Read ↗

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.Semantic proximity Read ↗

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.Semantic proximity Read ↗

A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect.Semantic proximity Read ↗

Polymorphisms contribution to the determination of significant risk of specific toxicities in multiple myeloma.Semantic proximity Read ↗

Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis.Semantic proximity Read ↗

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic valueSemantic proximity Read ↗

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.Semantic proximity Read ↗

PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple MyelomaSemantic proximity Read ↗

CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.